Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.3900 (-4.44%) ($8.3900 - $8.3900) on Tue. Mar. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.49% (three month average) | RSI | 51 | Latest Price | $8.3900(-4.44%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX advances 4.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(41%) XBI(41%) ARKK(37%) IBB(36%) ACES(34%) | Factors Impacting HTBX price | HTBX will decline at least -4.245% in a week (0% probabilities). VIXM(-25%) VXX(-21%) UUP(-16%) IGOV(-13%) XLU(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.245% (StdDev 8.49%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $8.51 | 5 Day Moving Average | $8.74(-4%) | 10 Day Moving Average | $8.4(-0.12%) | 20 Day Moving Average | $8.51(-1.41%) | To recent high | -33.1% | To recent low | 59.5% | Market Cap | $923m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |